"Designing Growth Strategies is in our DNA"

Cardiovascular Stents Market Size, Share and Industry Analysis By Product Type (Coronary Stenting, Peripheral Stenting), Stent Type (Drug Eluting Stents (DES), Bioresorbable Stents, Bare Metal Stents & Others), Disease Indication (Venous Disease, Arterial Disease), End User and Regional Forecast, 2018 - 2025

Region : Global | Latest Update: Sep, 2019 | Published Date: Apr, 2019 | Report ID: FBI100061| Status : Published



The global cardiovascular stents market size was valued at USD 7,838.9 Million in 2017, is projected to reach USD 13,100.2 Million by the end of 2025, exhibiting a CAGR of 6.6%.

Cardiovascular diseases are becoming increasingly common across the globe. Lifestyle-related heart diseases such as obesity and atherosclerosis are the key factors associated with the rising patient pool for invasive & minimally invasive procedures such as angioplasty. 

Angioplasty or percutaneous coronary intervention is a procedure that involves permanent placement of a tiny mesh tube, called a stent, to wide open the clogged artery or vein. The stent keeps the coronary & peripheral vasculature (arteries & veins) wide open, compressing the plaques, and reduces the chances of a heart attack. A consistent rise in the incidence of coronary artery diseases owing to the rapid adaption of a sedentary lifestyle by people around the world is a key factor associated with the rising procedures of percutaneous coronary intervention. Moreover, the introduction of technologically advanced stents by key manufacturers across the globe is projected to boost the cardiovascular stents market between 2018 and 2025.

Get comprehensive study about this report by, request a free sample copy

Coronary Stenting Procedure Type to Account for Highest Market Share by 2025

Increasing investment by emerging players in the research and development (R&D) of coronary stents to introduce novel & advanced coronary stents such as bioresorbable stents, bioengineered stents, etc. is a key factor associated with the rising uptake of coronary stents in the global market.

In terms of stent type, the global cardiovascular stents market is categorized into drug-eluting stents (DES), bare-metal stents, bioresorbable stents, and others. Of these, drug-eluting stents are expected to dominate the global cardiovascular stents market throughout the forecast period owing to the introduction of next-generation drugs for DES by key companies. Various disease indications in the cardiovascular stents market are venous diseases and arterial diseases. The venous disease segment is anticipated to grow with a maximum CAGR during 2018-2025. On the basis of end-user, the global cardiovascular stents market is segmented into hospitals, ambulatory surgery centers, specialty clinics, and catheterization labs.

To get details on market share, speak to our analyst

Government Participation in Price Capping of Cardiovascular Stents Augmenting the Market in the Asia Pacific at Highest CAGR

Asia Pacific is likely to grow at a significant CAGR during the forecast period. Improved distribution of cardiovascular stents by manufacturers and distributors in countries such as China and Australia is likely to propel the growth of cardiovascular stents market in the Asia Pacific with relatively significant CAGR. Price capping of stents in India to improve their accessibility is boosting the uptake of stents in India, which can be a key factor to boost the growth of the cardiovascular stents market in India during 2018-2025. North America generated revenue of US$ 2,344.9 Mn in 2017 and is expected to continue to remain dominant throughout the forecast period. Ongoing clinical trials on novel stents in the US. and green signal by regulatory authorities for the approval of stents are projected to augment the growth of North America's cardiovascular stents market during the forecast period.

Abbott, Medtronic, and Boston Scientific Corporation leading the global Cardiovascular Stents market

The current vendor landscape in the global cardiovascular stents market is consolidated owing to the remarkable distribution network of major companies in emerging economies. However, ongoing clinical studies being funded by public & private players is expected to increase the number of companies in the global cardiovascular stents market during the forecast period. Currently, Abbott, Medtronic, and Boston Scientific Corporation lead the market together constituting maximum market share. The scenario is likely to change owing to the market fluctuations in India. In 2018, Abbott withdrew its leading XIENCE Alpine stent from the Indian market, which is expected to affect its leading position in the global market during 2018-2025. Other players operating in the global cardiovascular stents market are Biotronik SE & Co. KG, Cardinal Health, Cook, C. R. Bard, Inc., MicroPort Scientific Corporation, Terumo Corporation, B. Braun Melsungen AG, and others.


North America Cardiovascular Stents Market, 2017

To get geographical overview of this market, request a free sample copy

Recent advancements in cardiac care are increasing awareness about cardiovascular diseases across the globe. The advancements in the percutaneous coronary interventions are improving the operational capabilities and reducing errors. The efficiency of stent placements is being enhanced owing to the availability of well-qualified interventional cardiologists across the globe.

The report provides qualitative and quantitative insights on the cardiovascular stents industry and detailed analysis of market size & growth rate for all possible segments in the market. The market is segmented on the basis of procedure type, stent type, disease indication, and end-user. On the basis of procedure type, the global cardiovascular stents market is categorized into coronary stenting & peripheral stenting. Various stent types covered in the report are drug-eluting stents (DES), bioresorbable stents, bare-metal stents, and others. In terms of disease indication, the market is categorized into venous diseases & arterial diseases, while various end-users in the report are hospitals, ambulatory surgery centers, specialty clinics, and catheterization labs. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries. 

To get information on various segments, share your queries with us

Along with this, the report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of key cardiovascular diseases (Peripheral Artery Diseases & Coronary Artery Diseases) by major countries, pricing analysis, recent industry developments such as partnerships, mergers & acquisitions, a regulatory scenario for key countries, and health reimbursement scenario for key countries.




By Product Type

  • Coronary Stenting

  • Peripheral Stenting

By Stent Type

  • Drug Eluting Stents (DES)

  • Bioresorbable Stents

  • Bare Metal Stents

  • Others

By Disease Indication

  • Venous Disease

  • Arterial Disease

By End User

  • Hospitals

  • Ambulatory Surgery Centers

  • Specialty Clinics

  • Catheterization Labs

By Geography

  • North America (USA and Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


  • Biotronik SE & Co. KG

  • Cardinal Health

  • Cook

  • C. R. Bard, Inc.

  • MicroPort Scientific Corporation

  • Terumo Corporation

  • B. Braun Melsungen AG

  • Abbott

  • Boston Scientific Corporation

  • Medtronic

  • Other players

Key Industry Developments

  • In February 2018, Medtronic announced the FDA approval and launch of Resolute Onyx 2.0 mm Drug-Eluting Stent (DES), which the smallest size Drug-Eluting Stent (DES) available in the market.

  • In October 2017, Abbott received CE approval for XIENCE Sierra, an everolimus-eluting coronary stent system for sale in all the CE mark countries

  • In July 2016, Abbott received FDA approval for Absorb GT1 BVS, an absorbable stent for the treatment of coronary artery disease.

Cardiovascular Stents Market Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2017
  • 2014-2016
  • 147


  • 4850
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.